A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy

References

• Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015;5(6):a022426–a022426. doi: 10.1101/cshperspect.a022426
   PubMed Web of Science ®Google Scholar
• Devinsky O, Vezzani A, O’Brien TJ, et al. Epilepsy. Nat Rev Dis Primers. 2018;4(1):4. doi: 10.1038/nrdp.2018.24
   PubMedGoogle Scholar
• Epilepsy. Pan American health Organisation/WHO. [cited20 Jan 2024]. Available from: https://www.paho.org/en/topics/epilepsy
   Google Scholar
• Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy. Neurology. 2017;88:296–303. doi: 10.1212/WNL.0000000000003509
   PubMed Web of Science ®Google Scholar
• Thijs RD, Surges R, O’Brien TJ, et al. Epilepsy in adults. Lancet. 2019;393(10172):689–701. doi: 10.1016/S0140-6736(18)32596-0
   PubMed Web of Science ®Google Scholar
• Garg D. Specific considerations for epilepsy in India. Curr Med Issues [Internet]. 2020;18(2):105. [cited 2024 Mar 28]. Available from: https://journals.lww.com/cmii/fulltext/2020/18020/specific_considerations_for_epilepsy_in_india.7.aspx
   Google Scholar
• Muñiz-Landeros CE. is it an epileptic seizure? Medicina Universitaria. 2015;17(67):122–125. doi: 10.1016/j.rmu.2015.03.002
   Google Scholar
• Epilepsy. American Association of Neurological Surgeons. [cited 2024 Jan 24]. Available from: https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Epilepsy
   Google Scholar
• Epilepsy [Internet]. [cited 2024 Feb 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/epilepsy
   Google Scholar
• Goldenberg, MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. Pharmacy and Therapeutics. 2010;35(7):392–415. https://pubmed.ncbi.nlm.nih.gov/20689626/
   Google Scholar
• Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35:935. doi: 10.1007/s40263-021-00827-8
   PubMed Web of Science ®Google Scholar
• Ventola, CL. Epilepsy management: newer agents, unmet needs, and future treatment strategies Pharmacy and therapeutics. 2014 Nov;39(11):776–92. https://pubmed.ncbi.nlm.nih.gov/25395820/
   Google Scholar
• Techniques to help with memory. Epilepsy Foundation. [Internet]. [cited 2024 Jan 20].Available from: https://www.epilepsy.com/complications-risks/thinking-and-memory/diagnosing-memory-problems/memory-techniques
   Google Scholar
• Miziak B, Chrościńska-Krawczyk M, Czuczwar SJ. Neurosteroids and Seizure Activity. Front Endocrinol. 2020;11:11. doi: 10.3389/fendo.2020.541802
   PubMed Web of Science ®Google Scholar
• Biagini G, Panuccio G, Avoli M. Neurosteroids and epilepsy. Curr Opin Neurol. 2010;23(2):170. doi: 10.1097/WCO.0b013e32833735cf
   PubMed Web of Science ®Google Scholar
• Rebas E, Rzajew J, Radzik T, et al. Neuroprotective polyphenols: a modulatory action on neurotransmitter pathways. Curr Neuropharmacol. 2020;18(5):431–445. doi: 10.2174/1570159X18666200106155127
   PubMed Web of Science ®Google Scholar
• Matias I, Buosi AS, Gomes FCA. Functions of flavonoids in the central nervous system: astrocytes as targets for natural compounds. Neurochem Int. 2016;95:85–91. doi: 10.1016/j.neuint.2016.01.009
   PubMed Web of Science ®Google Scholar
• Carver CM, Reddy DS. Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacol (Berl). 2013;230(2):151–188. doi: 10.1007/s00213-013-3276-5
   PubMed Web of Science ®Google Scholar
• Reddy DS. GABA-A receptors mediate tonic inhibition and neurosteroid sensitivity in the brain. Vitam Horm. 2018;107:177–191.
   PubMed Web of Science ®Google Scholar
• Ghit A, Assal D, Al-Shami AS, et al. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021;19(1):123. doi: 10.1186/s43141-021-00224-0
   PubMed Web of Science ®Google Scholar
• Vossler DG. Ganaxolone: a new treatment for CDKL5 deficiency disorder. Epilepsy Curr. 2022;22:348–350. doi: 10.1177/15357597221125238
   PubMed Web of Science ®Google Scholar
• Chuang SH, Reddy DS. Genetic and molecular regulation of extrasynaptic GABA-A receptors in the brain: therapeutic insights for epilepsy. J Pharmacol Exp Ther. 2018;364:180–197. doi: 10.1124/jpet.117.244673
   PubMed Web of Science ®Google Scholar
• St. Louis E, Rosenfeld W, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr Neuropharmacol. 2009;7(2):77–82. doi: 10.2174/157015909788848866
   PubMed Web of Science ®Google Scholar
• Turkmen S, Backstrom T, Wahlstrom G, et al. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol. 2011;162(2):311–327. doi: 10.1111/j.1476-5381.2010.01059.x
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):10. doi: 10.1186/s13643-021-01626-4
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Welch VA, editor. Cochrane; 2023. p. 1–694. www.training.cochrane.org/handbook
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. doi: 10.1136/bmj.l4898
   Web of Science ®Google Scholar
• Sullivan J, Gunning B, Zafar M, et al. Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy. Epilepsy Res. 2023;191:107112. doi: 10.1016/j.eplepsyres.2023.107112
   PubMed Web of Science ®Google Scholar
• Knight EMP, Amin S, Bahi-Buisson N, et al. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022;21(5):417–427. doi: 10.1016/S1474-4422(22)00077-1
   PubMed Web of Science ®Google Scholar
• Sperling MR, Klein P, Tsai J. Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures. Epilepsia. 2017;58:558–564. doi: 10.1111/epi.13705
   PubMed Web of Science ®Google Scholar
• Lappalainen J, Tsai J, Amerine W. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Focal-Onset Seizures (P5.237). Neurology. 2010;88(16). doi: 10.1212/WNL.88.16_supplement.P5.237
   Google Scholar
• Laxer K, Blum D, Abou-Khalil BW, et al. Assessment of ganaxolone’s anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone presurgical study group. Epilepsia. 2000;41(9):1187–1194. doi: 10.1111/j.1528-1157.2000.tb00324.x
   PubMed Web of Science ®Google Scholar
• Belelli D, Hogenkamp D, Gee KW, et al. Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor. Neurobiol Stress. 2019;12:12. doi: 10.1016/j.ynstr.2019.100207
   Web of Science ®Google Scholar
• Nohria V, Giller E. Ganaxolone. Neurotherapeutics. 2007;4:102–105. doi: 10.1016/j.nurt.2006.11.003
   PubMed Web of Science ®Google Scholar
• Keam SJ, Al-Salama ZT. Ganaxolone in seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: a profile of its use in the USA. Drugs Ther Perspect. 2023;39(3):81–88. doi: 10.1007/s40267-022-00976-w
   Google Scholar
• Gasior M, Ungard JT, Beekman M, et al. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology. 2000;39:1184–1196. doi: 10.1016/S0028-3908(99)00190-2
   PubMed Web of Science ®Google Scholar
• Reddy DS, Rogawski MA. Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model. Epilepsy Res. 2010;89(2–3):254–260. doi: 10.1016/j.eplepsyres.2010.01.009
   PubMed Web of Science ®Google Scholar
• Moncayo JA, Vargas MN, Castillo I, et al. Adjuvant treatment for protocadherin 19 (PCDH19) syndrome. Cureus. 2022;14. doi: 10.7759/cureus.27154
   Web of Science ®Google Scholar
• Monaghan EP, McAuley JW, Data JL. Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy. Expert Opin Investig Drugs. 1999;8(10):1663–1671. doi: 10.1517/13543784.8.10.1663
   PubMedGoogle Scholar